Acute Myeloid Leukemia (AML) is a cancer of the myeloid line of blood cells characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells—it is deadly. More than 20,000 Americans are diagnosed with AML and 10,000 die from the cancer annually. The five-year-survival rate for older adults remains dismal at less than 20 percent.
The Leukemia & Lymphoma Society (LLS) continues to deliver on its promise to “Beat AML,” the deadliest of the blood cancers, through its groundbreaking Beat AML® Master Clinical Trial, a precision medicine approach to treating these cancer patients. The first results of this trial, to be announced Sunday and Monday at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, validate the feasibility of using genomic sequencing to identify the patients’ specific type of acute myeloid leukemia (AML) and give them a targeted treatment within seven days, a first-ever approach to this disease, which, until recently, had not seen treatment advances in 40 years.
Brian Druker, MD, director of OHSU Knight Cancer InstituteSource: PR Newswire